12:00 AM
 | 
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

NeuTrexin trimetrexate glucuronate: Phase III data; marketed to treat Pneumocystis carinii pneumonia

Interim results from UBS's European Phase III trial showed a median survival time of 12.9 months for patients receiving NeuTrexin, 5-FU and leucovorin versus 10.1 months for those on 5-FU...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >